Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
Status:
Withdrawn
Trial end date:
2000-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill
them or deliver cancer-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to kill cancer cells. Combining monoclonal antibody therapy
with chemotherapy may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of rituximab followed by combination
chemotherapy in treating patients who have refractory or recurrent non-Hodgkin's lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Medstar Health Research Institute Washington Hospital Center